REFERENCES:
1.
Bassan
R, Hoelzer D, Thomas X, et al. Clinician Concepts of Cure in Adult
Relapsed and Refractory Philadelphia-Negative B Cell Precursor Acute
Lymphoblastic Leukemia: A Delphi Study. Adv Ther .
2019;36:870-879.
2.
Gökbuget
N, Dombret H, Giebel S, et al. Minimal residual disease level predicts
outcome in adults with Ph-negative B-precursor acute lymphoblastic
leukemia. Hematology (Luxembourg) . 2019;24:337-348.
3.
Kantarjian
HM, DeAngelo DJ, Stelljes M, et al. InOtuzumab Ozogamicin versus
Standard Therapy for Acute Lymphoblastic Leukemia. The New England
journal of medicine . 2016;375:740-753.
4.
Topp
MS, Gökbuget N, Zugmaier G, et al. Phase II Trial of the Anti-CD19
Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular
Remissions in Patients With Relapsed or Refractory B-Precursor Acute
Lymphoblastic Leukemia. J Clin Oncol . 2014;32:4134-4140.
5.
Maude
SL, Laetsch TW, Buechner J, et al, Tisagenlecleucel in Children and
Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med .
2018;378:439-448.
6.
Lanza
F, Maffini E, Rondoni M, et al. CD22 Expression in B-Cell Acute
Lymphoblastic Leukemia: Biological Significance and Implications for
InOtuzumab Therapy in Adults. Cancers (Basel) . 2020;12:303.
7.
Kantarjian
H, Thomas D, O’Brien S, et al. Long-term follow-up results of
hyperfractionated cyclophosphamide, vincristine, doxorubicin, and
dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute
lymphocytic leukemia. Cancer . 2004;101:2788-2801.
8.
Thomas
X. InOtuzumab ozogamicin in the treatment of B-cell acute lymphoblastic
leukemia. Expert Opin Investig Drugs . 2012;21:871-878.
9.
Kantarjian
HM, DeAngelo DJ, Stelljes M, et al. InOtuzumab ozogamicin versus
standard of care in relapsed or refractory acute lymphoblastic leukemia:
Final report and long‐term survival follow‐up from the randomized, phase
3 InO‐VATE study. Cancer . 2019;125:2474-2487.
10.
Jabbour
E, Gökbuget N, Advani A, et al. Impact of minimal residual disease
status in patients with relapsed/refractory acute lymphoblastic leukemia
treated with InOtuzumab ozogamicin in the phase III InO-VATE trial.Leuk Res . 2020;88:106283.
11.
Papayannidis
C, Sartor C, Dominietto A, et al. InOtuzumab ozogamicin and donor
lymphocyte infusion is a safe and promising combination in relapsed
acute lymphoblastic leukemia after allogeneic stem cell transplant.Hematol Oncol . 2021;39:580-583.
12.
Gauthier
J, Bezerra ED, Hirayama AV, et al. Factors associated with outcomes
after a second CD19-targeted CAR T-cell infusion for refractory B-cell
malignancies. Blood . 2021;137:323-335.
13.
Loren
AW, Porter DL. Donor leukocyte infusions for the treatment of relapsed
acute leukemia after allogeneic stem cell transplantation. Bone
Marrow Transplant . 2008;41:483-493.
24.
Chan
WYK, Lee PPW, Cheuk DKL, et al. Blinatumomab with donor lymphocyte
infusions post-haploidentical hematopoietic stem cell transplantation as
salvage therapy for relapsed refractory acute lymphoblastic leukemia
post
chimeric antigen receptor T-cell therapy. Pediatr Blood Cancer.
2022:e29852.